Page last updated: 2024-12-07

1-ethylphenoxathiin 10,10-dioxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-ethylphenoxathiin 10,10-dioxide is a chemical compound with the formula C14H14O3S. It is a white solid at room temperature.

**Importance in Research:**

**1. Anti-Cancer Properties:**

1-ethylphenoxathiin 10,10-dioxide has demonstrated promising anti-cancer activity in various studies. It has been shown to:

* **Inhibit the growth of cancer cells** in vitro and in vivo.
* **Induce apoptosis (programmed cell death)** in cancer cells.
* **Interfere with the signaling pathways** that promote cancer cell growth and survival.

**2. Anti-Inflammatory Properties:**

* **Reduce inflammation** by inhibiting the production of pro-inflammatory cytokines.
* **Potentially useful for treating inflammatory conditions** like arthritis, asthma, and inflammatory bowel disease.

**3. Anti-Bacterial Properties:**

* **Exhibits antimicrobial activity** against various bacteria, including drug-resistant strains.

**4. Neuroprotective Properties:**

* **May protect neurons from damage** caused by oxidative stress and neurodegenerative diseases.

**5. Potential for Drug Development:**

* Its diverse pharmacological properties have led to significant research interest in its potential as a drug candidate for various diseases.

**6. Chemical Probe for Research:**

* 1-ethylphenoxathiin 10,10-dioxide can serve as a chemical probe for studying biological processes, particularly those related to cancer and inflammation.

**Current Research and Future Directions:**

Research on 1-ethylphenoxathiin 10,10-dioxide continues to explore its potential therapeutic applications. Studies are ongoing to:

* **Optimize its pharmacological properties** through chemical modifications.
* **Develop safe and effective drug delivery systems** for clinical use.
* **Evaluate its efficacy in pre-clinical and clinical trials** for specific diseases.

Overall, 1-ethylphenoxathiin 10,10-dioxide is a promising compound with significant potential for the development of new drugs for the treatment of cancer, inflammation, and other diseases. Its unique structure and diverse biological activities make it an important focus of research in medicinal chemistry and pharmacology.

1-ethylphenoxathiin 10,10-dioxide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126111
CHEMBL ID66225
SCHEMBL ID3897015
MeSH IDM0204786

Synonyms (15)

Synonym
CHEMBL66225 ,
1-ethylphenoxathiine 10,10-dioxide
1-ethyl-phenoxathiine 10,10-dioxide
bdbm50009741
phenoxathiin, 1-ethyl-,10,10-dioxide
134476-36-1
1-ethylphenoxathiin 10,10-dioxide
unii-v8y35iom23
v8y35iom23 ,
bw-1370u87
phenoxathiin, 1-ethyl-, 10,10-dioxide
SCHEMBL3897015
HQSRQKBSOOZLHH-UHFFFAOYSA-N
DTXSID70158729
AKOS040748073
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)IC50 (µMol)0.05830.00071.979812.5000AID126050; AID126057
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)Ki0.01000.00190.55334.8000AID126213
Amine oxidase [flavin-containing] AHomo sapiens (human)Ki0.01000.00192.379710.0000AID125562
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID126057The compound was tested in vitro for inhibition of Monoamine Oxidase A from rat brain1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
A selective, reversible, competitive inhibitor of monoamine oxidase A containing no nitrogen, with negligible potentiation of tyramine-induced blood pressure rise.
AID125703In vivo effective dose against Monoamine Oxidase A in rat brain1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
A selective, reversible, competitive inhibitor of monoamine oxidase A containing no nitrogen, with negligible potentiation of tyramine-induced blood pressure rise.
AID125704The compound was tested ex vivo for inhibition of Monoamine Oxidase A in rat brain1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
A selective, reversible, competitive inhibitor of monoamine oxidase A containing no nitrogen, with negligible potentiation of tyramine-induced blood pressure rise.
AID127011Percentage inhibition of Monoamine oxidase B (MAO-B) activity at 0.1 uM concentration1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Selective inhibitors of monoamine oxidase (MAO). 5. 1-Substituted phenoxathiin inhibitors containing no nitrogen that inhibit MAO A by binding it to a hydrophobic site.
AID125705In vivo inhibitory activity against Monoamine oxidase A of rat brain1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Selective inhibitors of monoamine oxidase (MAO). 5. 1-Substituted phenoxathiin inhibitors containing no nitrogen that inhibit MAO A by binding it to a hydrophobic site.
AID126050Inhibitory concentration against monoamine oxidase A.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Selective inhibitors of monoamine oxidase (MAO). 5. 1-Substituted phenoxathiin inhibitors containing no nitrogen that inhibit MAO A by binding it to a hydrophobic site.
AID125562In vitro binding affinity towards Monoamine Oxidase A in human1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
A selective, reversible, competitive inhibitor of monoamine oxidase A containing no nitrogen, with negligible potentiation of tyramine-induced blood pressure rise.
AID126213In vitro binding affinity towards Monoamine Oxidase A in rat1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
A selective, reversible, competitive inhibitor of monoamine oxidase A containing no nitrogen, with negligible potentiation of tyramine-induced blood pressure rise.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (33.33%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]